139 related articles for article (PubMed ID: 35860907)
1. Optimization of prostate cancer patient lymph node staging via the integration of neutrophil-lymphocyte ratios, platelet-lymphocyte ratios, and
Wang Y; Tang Y; Gao X; Gan Y; Hu S; Chen MF; Cai Y
Prostate; 2022 Nov; 82(15):1415-1421. PubMed ID: 35860907
[TBL] [Abstract][Full Text] [Related]
2. How accurate is
Erdem S; Simsek DH; Degirmenci E; Aydin R; Bagbudar S; Ozluk Y; Sanli Y; Sanli O; Ozcan F
Urol Oncol; 2022 Jan; 40(1):6.e1-6.e9. PubMed ID: 34400066
[TBL] [Abstract][Full Text] [Related]
3. Histological comparison between predictive value of preoperative 3-T multiparametric MRI and
Franklin A; Yaxley WJ; Raveenthiran S; Coughlin G; Gianduzzo T; Kua B; McEwan L; Wong D; Delahunt B; Egevad L; Samaratunga H; Brown N; Parkinson R; Roberts MJ; Yaxley JW
BJU Int; 2021 Jan; 127(1):71-79. PubMed ID: 32524748
[TBL] [Abstract][Full Text] [Related]
4. Clinical parameters and nomograms for predicting lymph node metastasis detected with
Onal C; Ozyigit G; Oymak E; Guler OC; Hurmuz P; Tilki B; Reyhan M; Tuncel M; Akyol F
Prostate; 2021 Jul; 81(10):648-656. PubMed ID: 33949694
[TBL] [Abstract][Full Text] [Related]
5. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
6. Primary lymph-node staging with
Corona-Montes VE; González-Cuenca E; Fernández-Noyola G; Olarte-Casas MA; Bobadilla-Salazar D; Medrano-Urtecho HM; Asimakopoulos AD
Urol Oncol; 2021 Aug; 39(8):494.e1-494.e6. PubMed ID: 33223371
[TBL] [Abstract][Full Text] [Related]
7. 18 F-prostate specific membrane antigen positron emission tomography/computerized tomography for lymph node staging in medium/high risk prostate cancer: A systematic review and meta-analysis.
Lv Z; Song L; Wang M; Hou H; Li H; Wang X; Wang J; Wang J; Liu M
Chin Med J (Engl); 2024 Apr; 137(8):949-958. PubMed ID: 37690993
[TBL] [Abstract][Full Text] [Related]
8. Accuracy of 68Ga-PSMA PET-CT and PET-MRI in lymph node staging for localized prostate cancer.
Barbosa ÁRG; Amaral BS; Lourenço DB; Bianco B; Gushiken FA; Apezzato M; Silva JF; Cunha MLD; Filippi RZ; Baroni RH; Lemos GC; Carneiro A
Einstein (Sao Paulo); 2022; 20():eAO6599. PubMed ID: 35584444
[TBL] [Abstract][Full Text] [Related]
9.
Esen T; Falay O; Tarim K; Armutlu A; Koseoglu E; Kilic M; Seymen H; Sarikaya AF; Kiremit MC; Balbay MD; Canda AE; Baydar DE; Kordan Y; Demirkol MO; Tilki D
Eur Urol Focus; 2021 Mar; 7(2):288-293. PubMed ID: 33509671
[TBL] [Abstract][Full Text] [Related]
10. Incremental Impact of [
Szigeti F; Schweighofer-Zwink G; Meissnitzer M; Hauser-Kronberger C; Hitzl W; Kunit T; Forstner R; Pirich C; Beheshti M
Mol Imaging Biol; 2022 Feb; 24(1):50-59. PubMed ID: 34519966
[TBL] [Abstract][Full Text] [Related]
11.
Klingenberg S; Jochumsen MR; Ulhøi BP; Fredsøe J; Sørensen KD; Borre M; Bouchelouche K
J Nucl Med; 2021 Feb; 62(2):214-220. PubMed ID: 32444374
[TBL] [Abstract][Full Text] [Related]
12. Use of gallium-68 prostate-specific membrane antigen positron-emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature.
Luiting HB; van Leeuwen PJ; Busstra MB; Brabander T; van der Poel HG; Donswijk ML; Vis AN; Emmett L; Stricker PD; Roobol MJ
BJU Int; 2020 Feb; 125(2):206-214. PubMed ID: 31680398
[TBL] [Abstract][Full Text] [Related]
13. Risk of metastatic disease on
Yaxley JW; Raveenthiran S; Nouhaud FX; Samaratunga H; Yaxley WJ; Coughlin G; Yaxley AJ; Gianduzzo T; Kua B; McEwan L; Wong D
BJU Int; 2019 Sep; 124(3):401-407. PubMed ID: 31141284
[TBL] [Abstract][Full Text] [Related]
14. Rational use of Ga-68 PSMA PET-CT according to nomograms and risk groups for the detection of lymph node metastasis in prostate cancer.
Madendere S; Kılıç M; Köseoğlu E; Aykanat İC; Eden AB; Coşkun B; Tekkalan FB; Balbay MD
Urol Oncol; 2024 Feb; 42(2):29.e9-29.e15. PubMed ID: 38114351
[TBL] [Abstract][Full Text] [Related]
15.
Herlemann A; Wenter V; Kretschmer A; Thierfelder KM; Bartenstein P; Faber C; Gildehaus FJ; Stief CG; Gratzke C; Fendler WP
Eur Urol; 2016 Oct; 70(4):553-557. PubMed ID: 26810345
[TBL] [Abstract][Full Text] [Related]
16. Establishment and prospective validation of an SUV
Jiao J; Kang F; Zhang J; Quan Z; Wen W; Zhao X; Ma S; Wu P; Yang F; Guo W; Yang X; Yuan J; Shi Y; Wang J; Qin W
Theranostics; 2021; 11(17):8396-8411. PubMed ID: 34373749
[No Abstract] [Full Text] [Related]
17. Outcomes of Primary Lymph Node Staging of Intermediate and High Risk Prostate Cancer with
Yaxley JW; Raveenthiran S; Nouhaud FX; Samartunga H; Yaxley AJ; Coughlin G; Delahunt B; Egevad L; McEwan L; Wong D
J Urol; 2019 Apr; 201(4):815-820. PubMed ID: 30672842
[TBL] [Abstract][Full Text] [Related]
18. Comparison of
Zhang Q; Zang S; Zhang C; Fu Y; Lv X; Zhang Q; Deng Y; Zhang C; Luo R; Zhao X; Wang W; Wang F; Guo H
J Transl Med; 2017 Nov; 15(1):230. PubMed ID: 29115970
[TBL] [Abstract][Full Text] [Related]
19.
von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
[TBL] [Abstract][Full Text] [Related]
20. Distribution of prostate cancer recurrences on gallium-68 prostate-specific membrane antigen (
Huits TH; Luiting HB; van der Poel HG; Nandurkar R; Donswijk M; Schaake E; Vogel W; Roobol MJ; Wit E; Stricker P; Emmett L; van Leeuwen PJ
BJU Int; 2020 Jun; 125(6):876-883. PubMed ID: 32181951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]